Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAM use survey

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplements and herbals are the second most common form of CAM used by people age 50 and older, according to a survey recently released by the National Center for Complementary and Alternative Medicine and AARP. Supplements were used by 42% of respondents, while 45% of survey participants had used massage or chiropractic therapy, 15% had used mind/body practices such as meditation or hypnosis and 14% had used naturopathy or acupuncture. Additionally, 31% of respondents who had used CAM said they had discussed it with their physician. Among those who had not spoken to a physician about their CAM use, 42% said it was because the physician had never asked, while 30% said it was because they did not know they should. The study, a telephone survey of 1,559 people, was conducted in spring 2006...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel